Raphael Pharmaceutical (RAPH) Income from Continuing Operations (2020 - 2024)
Raphael Pharmaceutical (RAPH) posted Income from Continuing Operations of 1932000.0 for Q4 2024, down 505.64% sequentially from 319000.0 in Q3 2024, and down 70.07% YoY from 6455152.94 in Q1 2024.
Raphael Pharmaceutical (RAPH) Income from Continuing Operations (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical has reported Income from Continuing Operations for 5 years, with the latest figure at 1932000.0 in Q4 2024.
- Quarterly Income from Continuing Operations fell 70.07% year-over-year to 1932000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 3047000.0 (down 19.87% YoY) and the FY2025 annual result came in at 3232000.0, down 6.07% from the prior year.
- Income from Continuing Operations eased to 1932000.0 in Q4 2024 per RAPH's latest filing, from 319000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 175000.0 in Q1 2022 and troughed at 1932000.0 in Q4 2024.
- A 5-year average of 758235.29 and a median of 419000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2024: Income from Continuing Operations slumped 371.95% in 2021, then jumped 56.24% in 2024.
- Over 5 years, Income from Continuing Operations stood at 385000.0 in 2020, then tumbled by 371.95% to 1817000.0 in 2021, then retreated by 0.77% to 1831000.0 in 2022, then surged by 37.96% to 1136000.0 in 2023, then sank by 70.07% to 1932000.0 in 2024.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1932000.0, 319000.0, and 249000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | -199,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.93 Mn |
| Sep 30, 2024 | -319,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -547,000.00 |
| Dec 31, 2023 | -1.14 Mn |
| Sep 30, 2023 | -729,000.00 |
| Jun 30, 2023 | -419,000.00 |
| Mar 31, 2023 | -258,000.00 |
| Dec 31, 2022 | -1.83 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -612,000.00 |
| Mar 31, 2022 | -175,000.00 |
| Dec 31, 2021 | -1.82 Mn |
| Sep 30, 2021 | -418,000.00 |
| Jun 30, 2021 | -385,000.00 |
| Mar 31, 2021 | -252,000.00 |
| Dec 31, 2020 | -385,000.00 |